retatrutide weight loss clinical trials results just posted Phase 3 trial showing up to 30% body over 80 weeks. That is approaching bariatric surgery territory, from a medication., It targets three hormone pathways: Medscape | Retatrutide, Eli Lilly's

95% CI 0.630.98) and reduced risks of sepsis and infection-related mortality compared with those using dipeptidyl peptidase-4 inhibitors (115)

Medicaid spending on GLP-1s for all conditions increased from $597.3 million for about 755,000 prescriptions in 2019, to $3.9 billion for 3.8 million prescriptions in 2023, according to KFF

In some cases, blood sugar reductions among those taking bofanglutide were slightly greater than those taking semaglutide

People philosophically opposed to pharmaceutical interventions or preferring natural approaches benefit from having legitimate options backed by some research rather than completely unsubstantiated supplements

Liver health is a primary concern

a novel role of GLP-1 receptor agonists in cirrhotic cardiomyopathy